Biohit Oyj - Changes board/management/auditors

Biohit Oyj’s CEO Semi Korpela will return to work on 20.2.2017

Biohit Oyj Stock Exchange Release February 20, 2017 9:29 am local time (EEST)

Biohit Oyj announced on January 5, 2017 that CEO Semi Korpela would take a sick
leave of approximately one month, related to pneumonia and recovery from it. 

Korpela has recovered from his illness and will return to work on 20.2.2017.

“I am full of energy”, says CEO Semi Korpela.

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com



Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com